Healthcare / Medical Instruments & SuppliesIstanbul
$5.40
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $72.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
180.0x
↑EV/EBITDA
49.8x
↑ROE
-8.0%
↓Gross Margin
30.3%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
—
FCF margin
29.7%
FCF / Net income
-1.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $242.2M · net income $-39.5M · FCF $72.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $242.2M | $242.2M | $300.4M | $283.1M | $212.9M |
| Net Income | $-39.5M | $-39.5M | $-115.5M | $-73.8M | $51.1M |
| EBITDA | $21.5M | $21.5M | $-95.0M | $-53.1M | $82.6M |
| EPS | -0.20 | -0.20 | -0.58 | -0.53 | 0.63 |
| Gross Margin | 30.3% | 30.3% | 19.6% | 30.0% | 45.9% |
| Operating Margin | -8.2% | -8.2% | -9.1% | 2.4% | 26.3% |
| Net Margin | -16.3% | -16.3% | -38.4% | -26.1% | 24.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.10 | 0.15 |
| Current Ratio | 6.82 | 6.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $72.0M | $72.0M | $-102.0M | $76.1M | $-33.8M |
| Returns | |||||
| ROE | -8.0% | -8.0% | -21.6% | -22.0% | 18.1% |
| Valuation | |||||
| P/E | 180.00 | 180.00 | — | — | 10.10 |
| EV/EBITDA | 49.79 | 49.79 | — | — | 6.34 |
| P/B | 2.18 | 2.18 | 1.20 | 2.38 | 1.84 |
| Growth & Yield | |||||
| Revenue Growth | -19.4% | -19.4% | 6.1% | 32.9% | — |
| EPS Growth | 65.5% | 65.5% | -8.7% | -185.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+90.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.58 → -0.20
Residual
+90.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.